Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer
- PMID: 10382127
- DOI: 10.1046/j.1523-5378.1999.98281.x
Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer
Abstract
Background: Bismuth triple therapy provides consistently good results in Helicobacter pylori eradication worldwide, whereas quadruple therapy using a combination of omeprazole and bismuth triple regimen has produced cure rates in excess of 90%. The prevalence of metronidazole-resistant strains was 26.8% in our area. Colloidal bismuth pectin (CBP) is a new, lower-priced bismuth salt made in China. The purpose of this study was to investigate the efficacy and safety of CBP triple and quadruple regimens in the treatment of H. pylori-positive duodenal ulcer.
Materials and methods: In this prospective trial, 205 patients with H. pylori-positive duodenal ulcer were allocated randomly to receive one of four regimens: metronidazole, 200 mg; amoxicillin, 250 mg; and colloidal bismuth subcitrate (CBS), 120 mg (group 1), or CBP, 100 mg qid (group 2) for 2 weeks, then continued CBS, 240 mg, or CBP, 200 mg bid for a further 2 weeks. A quadruple regimen using a combination of omeprazole, 20 mg bid, and CBS triple therapy (group 3) or CBP triple therapy (group 4), respectively, was given to patients for 1 week, followed by omeprazole, 20 mg once daily for a further 3 weeks. Further endoscopy was performed at least 4 weeks after cessation of the treatment. H. pylori status was determined by histology, a 14C urea breath test, and a urease test.
Results: The per-protocol H. pylori cure rates were 85% (22 of 26 patients), 90% (35 of 39), 96% (46 of 48), and 95% (75 of 79) for groups 1 through 4. In the intention-to-treat analysis, cure rates were 79% (22 of 28), 83% (35 of 42), 90% (46 of 51), and 89% (75 of 84), respectively. The cure rates of quadruple therapy were higher than those of triple therapy; an 8.2% difference was not statistically significant (95% confidence interval [CI], 2.3-18.7%). The ulcer-healing rates were 88%, 87%, 98%, and 97%, respectively, for groups 1 through 4. The ulcer pain was relieved more rapidly in quadruple- than in triple-therapy regimens. Two patients discontinued treatment prematurely owing to drug-related side effects.
Conclusion: One-week quadruple therapy is highly effective and safe in H. pylori eradication in Chinese patients. CBP is as effective as CBS.
Similar articles
-
Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.Am J Gastroenterol. 2003 Mar;98(3):562-7. doi: 10.1111/j.1572-0241.2003.t01-1-07288.x. Am J Gastroenterol. 2003. PMID: 12650788 Clinical Trial.
-
Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.Eur J Gastroenterol Hepatol. 1994 Dec;6 Suppl 1:S103-7. Eur J Gastroenterol Hepatol. 1994. PMID: 7735924 Clinical Trial.
-
Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.Aliment Pharmacol Ther. 2002 Jul;16(7):1277-82. doi: 10.1046/j.1365-2036.2002.01299.x. Aliment Pharmacol Ther. 2002. PMID: 12144577 Clinical Trial.
-
Cure of Helicobacter pylori-associated ulcer disease through eradication.Baillieres Best Pract Res Clin Gastroenterol. 2000 Feb;14(1):119-32. doi: 10.1053/bega.1999.0063. Baillieres Best Pract Res Clin Gastroenterol. 2000. PMID: 10749093 Review.
-
Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China.Eur J Gastroenterol Hepatol. 2013 Oct;25(10):1134-40. doi: 10.1097/MEG.0b013e3283633b57. Eur J Gastroenterol Hepatol. 2013. PMID: 23778309 Free PMC article. Review.
Cited by
-
Cost-effectiveness analysis of two routine therapeutic methods for Helicobacter pylori eradication: a Persian cohort-based study.Gastroenterol Hepatol Bed Bench. 2021 Summer;14(3):250-259. Gastroenterol Hepatol Bed Bench. 2021. PMID: 34221265 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical